Researchers track safety of ALS drug tofersen in 7-Year registry study
NCT ID NCT07259980
First seen Jan 07, 2026 · Last updated May 16, 2026 · Updated 18 times
Summary
This study looks at the long-term safety of the drug tofersen (Qalsody) in people with a rare, inherited form of ALS called SOD1-ALS. Researchers will collect health information from about 125 participants in Europe and the U.S. over at least 7 years, without changing their medical care. The main goal is to track serious side effects and understand the health of people taking this medication.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AMYOTROPHIC LATERAL SCLEROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Mass General Hospital -MGH
RECRUITINGBoston, Massachusetts, 02114, United States
Contact Phone: •••-•••-••••
Contact
Conditions
Explore the condition pages connected to this study.